Could AAT be the answer to COVID-19 ARDS?
Clinical study finds alpha-1 antitryspin (AAT) reduces pro-inflammatory IL-6 and therefore may benefit COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS).
List view / Grid view
News
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, March 2022
EMA’s pharmacovigilance committee recommends product information updates for two COVID-19 vaccines - Janssen COVID-19 Vaccine and Moderna’s Spikevax.
New green synthesis method to enhance sustainability and benefit IBD
A novel flow synthesis method using recoverable solvents will be used to supply NEt-3IB, an inflammatory bowel disease (IBD) drug candidate.
Novel radioligand therapy shows promise in metastatic prostate cancer
New data suggests 225Ac-PSMA-617 radioligand therapy could improve overall survival in metastatic prostate cancer patients.
Efanesoctocog alfa prevents bleeding episodes in haemophilia A patients
Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients, according to new Phase III data.
Kisqali increases overall survival in advanced breast cancer patients by 12 months
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
New agreement makes “Africa’s own COVID-19 vaccine” a reality
Under a new agreement with J&J, Aspen SA Operations will be able to manufacture and make available Aspen-branded COVID-19 vaccines in Africa.
Global LIMS market to grow to $3.56bn by 2030
Research suggests rising demand for lab automation will help promote the growth of the laboratory information management system (LIMS) market.
Could LAPP enable end-to-end lab automation?
The robotic laboratory automation Plug & Play (LAPP) framework has been proposed to enable the integration of different robotic system components.
Trodelvy® improves breast cancer progression-free survival, finds study
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients.
Phase III study shows safety of fezolinetant as non-hormonal treatment of VMS
The safety and efficacy of fezolinetant is being evaluated in the Phase III trial of over 1,800 women seeking relief from severe vasomotor symptoms associated with menopause (VMS).
Chikungunya vaccine candidate safe and immunogenic in Phase III
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly.
PRIME scheme benefits drug development, finds EMA report
The report outlines the positive impact the EMA’s PRIority Medicines (PRIME) scheme has had on drug development for unmet medical need over the last five years.
£260mn in funding to support UK clinical research and medicines manufacturing
The UK Government has committed £200mn to support NHS-led diagnostics and treatment research and £60 million to expand life sciences manufacturing.
Empagliflozin benefits adults hospitalised for acute heart failure, shows study
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
